



COMMUNITY-ACQUIRED PNEUMONIA IN POPULATION

Khaled Ibrahim Alqurashi^{1*}, Abdulhamid Abdulnaeim Alsaigh², Jamal Sharaf Alzahrani³, Waleed Mohammed Omar Almahaili⁴, Roaa Khaled Alhelfawi⁵, Abdulrahman Abdulwasee Alsaigh⁶, Mohammed Abdalrhman Almasoumi⁷, Ahmed Nabeel Khawandanah⁸, Yazeed Saleh Alharthi⁹, Arwa Sultan Alnemry¹⁰, Mohammed Jaber Alomairi¹¹

Abstract:

Community-acquired pneumonia is the most contagious illness cause of death. We summarize newly released findings regarding the etiology of Community-acquired pneumonia in adults, efficiency of injections versus Streptococcus pneumoniae, diagnostics, and review the current therapy options. The research for eligible articles as of June 2022 through PubMed, and Embase. We have used the following search MeSh terms for PubMed: (community acquired pneumonia), Treatment and diagnosis Community-acquired pneumonia is a significant cause of infectious illness mortality, with an increasing prevalence with age. With an aging population, CAP will undoubtedly remain a worldwide problem. Although Streptococcus pneumoniae is still the most commonly isolated infection in CAP, the relative incidence of other pathogens has increased. Comorbidities and other risk factors should trigger medical suspicion. Advances in immunization, such as the introduction of PCV and subsequent herd resistance, as well as the potential use of PCV in adults, should help minimize the amount of sickness caused by *S. pneumoniae*.

^{1*,2,3,4,5,7,11}healthcare cluster at Makkah

⁶Directorate of health affairs Makkah

⁸Aleskan Primary health care Makkah

⁹Khulais General Hospital Makkah

¹⁰Aladel Primary health care Makkah

***Corresponding Author:** Khaled Ibrahim alqurashi

*Healthcare Cluster at Makkah

DOI: 10.53555/ecb/2022.11.10.87

Introduction:

Community-acquired pneumonia is the most common cause of infectious ailment related mortality around the world [1]. The epidemiology of Community-acquired pneumonia varies depend on geographical area, medical care setup and researched populace, with estimated incidences in between five and 11 per 1000 adults in Europe and North America [1]. Current European studies reveal a general yearly rate of hospitalization with CAP of 3.6 - 8.5 per 1000 adults, although this rises to 13.4 per 1000 persons in those over 65 years [2]. Community-acquired pneumonia (CAP) is the leading cause of death from a communicable infection. We present freshly published studies on the etiology of CAP in adults, the efficacy of injections versus *Streptococcus pneumoniae*, diagnostics, and current treatment choices.

Methodology:

We searched PubMed and Embase for relevant publications as of June 2022. We searched PubMed using the following MeSh terms: (community acquired pneumonia), Diagnosis, and Treatment. In addition, we reviewed the reference lists of the included research for other relevant literature. Then we narrowed our search to English language studies involving human participants.

Discussion:

Common pathogens contributing in CAP:

The microbiological causes of CAP vary by location, although *Streptococcus pneumoniae* is one of the most commonly isolated pathogens. Other often identified bacterial infections include *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Haemophilus flus*, and Gram-negative pathogens in specific locations [1]. Furthermore, a boosted sequence of respiratory viruses is usually identified in CAP patients and may produce a primary viral pneumonia or a subsequent bacterial pneumonia as a result of the infection's impact on lung host defense [3]. The recent development of the unique viral pathogens Middle East respiratory system sickness coronavirus is cause for concern and a new avian influenza A strain H7N9[3]. MERS CoV causes severe respiratory system failure, frequently coupled with renal failure, and has an inpatient mortality rate of more than 40% [4]. It belongs to the same genus as the severe acute respiratory system illness coronavirus. At the moment, therapy options are only encouraging, and the amount of breathing failure may demand extracorporeal membrane layer oxygenation. Fortunately, the transmission rate is minimal, with only about 5%

of household contacts impacted [4]. With one known case of camel-to-human transmission, dromedary camels appear to have been the animal reservoir. [3]. There has not been substantial dissemination of this infection beyond the Middle East, and also within that area the virus has actually just caused a minimal variety of human infections. There are no records of human to-human spread of H7N9 avian influenza A and this remains an erratic infection constrained to China [5].

• EFFECTS AND POSSIBILITY OF THE CONJUGATED S. PNEUMONIAE VACCINE

The efficacy of pneumovax, the grown-up vaccination for *S. pneumoniae*, at protecting against CAP is restricted [5]. In contrast, inoculation of Treatment and diagnosis CAP is a significant cause of infectious illness mortality, with an increasing prevalence with age. With an aging population, CAP will undoubtedly remain a worldwide problem. Although *Streptococcus pneumoniae* is still the most commonly isolated infection in CAP, the relative incidence of other pathogens has increased. Comorbidities and other risk factors should trigger medical suspicion. Advances in immunization, such as the introduction of PCV and subsequent herd resistance, as well as the potential use of PCV in adults, should help minimize the amount of sickness caused by *S. pneumoniae*., with current information revealing further benefit of the extended valency PCV-13 that shields against 13 *S. pneumoniae* serotypes[6]. A higher proportion of bacteraemic CAP is brought on by vaccine serotypes, suggesting that the vaccine may have a specific advantage in decreasing the incidence of extra extreme cases of *S. pneumoniae* CAP. However, there are in total at least 93 serotypes of *S. pneumoniae* and the leading serotypes causing disease differ with geography. This has pair of major repercussions. First as the present vaccinations are tailored for Europe and North America populaces they may not be as reliable in various other populaces [6]. Second of all, the minimal coverage of *S. pneumoniae* serotypes suggests that the efficacy of the vaccination is balanced out by raising prevalence of nonvaccine serotypes such as 6C, 8, 15A, 22, 23B and 35B amongst situations of *S. pneumoniae* pneumonia [6]. This serotype-replacement disease mores than time most likely to decrease the herd immunity advantages versus adult CAP of immunizing children. A current trial has actually evaluated the efficacy of using PCV-13 as a vaccine in grownups for preventing CAP. The data are as yet

unpublished, however the abstract that has been published recommends the vaccine was partially effective at protecting against CAP due to vaccination serotypes. Potentially, in the future, adults will certainly be immunized with the conjugated rather than the existing unconjugated vaccine, or perhaps a mix of both. Nevertheless, as a result of the better variety of serotypes prevalent in grownups compared with kids, serotype substitute will stay a major prospective problem. Choice of serotypes for future PCV preparations may likewise need to take account of the impacts

of capsular serotype on *S. pneumoniae* phenotype. For example, cases of CAP are controlled by serotype 14, 1, 8, 3 and 19A, respiratory system inability is associated with serotypes 3, 19A or 19F and cases of difficult CAP consisting of parapneumonic effusions are related to serotypes 1, 3, 7F, 14 and 19A[7]. Thus, future PCV solutions can particularly target these serotypes in order to protect against the much more extreme forms of *S. pneumoniae* CAP.




FIGURE 1. Average annual rates of the United States hospitalizations for pneumonia before and after the introduction of PCV7, according to age group [6].

Differential Diagnosis

Although *Streptococcus pneumoniae* remains the most commonly isolated infection in CAP, the

frequency of other pathogens has increased. Comorbidities and other risk factors should motivate clinical suspicion (Table 1) [8].

Table 1. Risk Factors and Pathogens in Community-Acquired Pneumonia [8].

RISK FACTOR	RELATED PATHOGENS
Alcoholism	Anaerobic oral flora, <i>Klebsiella pneumoniae</i> , <i>Mycobacterium tuberculosis</i> , <i>Streptococcus pneumoniae</i>
Aspiration	Anaerobic oral flora
Bioterrorism	<i>Bacillus anthracis</i> (anthrax), <i>Francisella tularensis</i> (tularemia), <i>Yersinia pestis</i> (plague)
Chronic obstructive pulmonary disease or smoking	<i>Chlamydophila pneumoniae</i> , <i>Haemophilus influenzae</i> , <i>Legionella</i> species, <i>Moraxella catarrhalis</i> , <i>Pseudomonas aeruginosa</i> or other gram-negative rods, <i>S. pneumoniae</i>
Exposure to bat or bird droppings	<i>Histoplasma capsulatum</i>
Exposure to farm animals or parturient cats	<i>Coxiella burnetii</i> (Q fever)
HIV infection (early)	<i>H. influenzae</i> , <i>M. tuberculosis</i> , <i>S. pneumoniae</i>
HIV infection (late)	<i>Aspergillus</i> and <i>Cryptococcus</i> species, <i>H. capsulatum</i> , <i>H. influenzae</i> , <i>Nocardia</i> species, nontuberculous mycobacteria, <i>Pneumocystis jiroveci</i>

Hotel or cruise ship travel in past two weeks	<i>Legionella</i> species
Influenza active in community	<i>H. influenzae</i> , influenza and other respiratory viruses, <i>S. pneumoniae</i> , <i>Staphylococcus aureus</i> (including MRSA)
Injection drug use	Anaerobes, <i>M. tuberculosis</i> , <i>S. aureus</i> (including MRSA), <i>S. pneumoniae</i>
Lung abscess	Anaerobic oral flora, <i>M. tuberculosis</i> , nontuberculous mycobacteria, <i>S. aureus</i> (including MRSA)
Travel to or residence in Middle East	Middle East respiratory syndrome
Travel to or residence in Southeast Asia and East Asia	Avian influenza, severe acute respiratory syndrome
Travel to or residence in southeastern and south-central states bordering the Mississippi and Ohio River basins	<i>Blastomyces dermatitidis</i>
Travel to or residence in southwestern United States	<i>Coccidioides</i> species, <i>Hantavirus</i> species

HIV = human immunodeficiency virus; MRSA = methicillin-resistant *Staphylococcus aureus*.

Radiography

Chest radiography (posteroanterior and lateral sights) has been revealed to be an important element in detecting pneumonia [9,10]. According to the latest American Thoracic Society (ATS) standards for the diagnosis and treatment of adults with CAP, "all patients with suspected CAP should have a chest radiograph to develop the diagnosis and recognize difficulties (pleural effusion, multilobar ailment)" [10]. Chest radiography might expose a lobar debt consolidation, which is standard in common pneumonia; or it can reveal bilateral, extra scattered infiltrates than those frequently seen in atypical pneumonia. Nevertheless, breast radiography carried out early in the course of the disease could be negative.

Laboratory Tests

Historically, common clinical examinations for pneumonia have actually included leukocyte matter, sputum Gram stain, pair of series of blood cultures, and urine antigens. However, the validity of these tests has actually lately been doubted after reduced positive culture rates were discovered (e.g., culture isolates of *S. pneumoniae* existed in only 40 to 50 percent of cases) [11]. Such reduced favorable society rates are likely as a result of problems with retrieving examples from the lower breathing system, previous administration of antibiotics, contamination from the upper necks muscles, faulty splitting up of sputum from saliva when streaking slides or plates, or viral etiology.

Furthermore, sputum examples are appropriate in only 52.3 percent of patients with CAP, and only 44 percent of those examples contain virus [11]. Nevertheless, preliminary treatment usually is directed by the presumption that the presenting disease is brought on by a common bacterial pathogen.

Results also called into question the scientific utility of obtaining blood cultures from patients with believed CAP. In a research study of CAP cases in 19 Canadian health centers over a six-month period, favorable blood cultures were acquired in only 5.2 to 6.2 percent of patients, including those with the most serious condition [12]. Based upon these findings, other researchers concluded that a positive blood culture had no correlation with the seriousness of the illness or outcome. One more possible research study revealed that blood cultures were positive in just 10.5 percent of patients with pneumonia [10]. In spite of these and other research study discoveries, current ATS guidelines recommend that patients hospitalized for thought CAP receive 2 collections of blood cultures. Blood cultures, nevertheless, are not necessary for outpatient medical diagnosis [10]. *Legionella* antigens were found in the urine of 48 percent of patients with thought *Legionella pneumophila* serogroup 1 infection [13]. Table 2 includes the level of sensitivity and specificity of analysis examinations for CAP.

TABLE 2. Sensitivity and Specificity of Diagnostic Tests for CAP [10],[13],[14].

DIAGNOSTIC TESTS BY PATHOGEN	SENSITIVITY (%)	SPECIFICITY (%)
Chlamydia		
Rapid PCR (sputum, BAL fluid)	30 to 95	>95
Serology (fourfold rise in serum and convalescent titers)	10 to 100	—
Sputum culture	10 to 80	>95
Gram-negative rods		
Sputum Gram stain	15 to 100	11 to 100
<i>Haemophilus influenzae, Moraxella catarrhalis, Pneumoniae</i>		
Sputum culture	Diagnostic yield 20 to 79*	Diagnostic yield 20 to 79*
Influenza		
Rapid DFA (sputum, BAL fluid)	22 to 75	90
<i>Legionella pneumophila</i>		
DFA (sputum, BAL fluid)	22 to 75	90
PCR (sputum, BAL fluid)	83 to 100	>95
Serum acute titer	10 to 27	>85
Urinary antigen	55 to 90	>95
<i>Mycoplasma pneumoniae</i>		
Antibiotic titers	75 to 95	>90
Cold agglutinins	50 to 60	—
PCR (sputum, BAL fluid)	30 to 95	>95
<i>Pneumococcal pneumoniae</i>		
Chest radiography (lobar infiltrate)	40†	—
Sputum culture	Diagnostic yield 20 to 79*	Diagnostic yield 20 to 79*
Sputum Gram stain	15 to 100	11 to 100

CAP = community-acquired pneumonia; PCR = polymerase chain reaction; BAL = bronchoalveolar lavage; DFA = direct fluorescence antibody.

*—Overgrowth of oral flora, isolation of atypical agents requires special media.

†—Acute symptoms.

• MANAGEMENT

Outpatient vs. Inpatient treatment

Selecting amongst outpatient and inpatient therapy is a crucial decision as a result of the feasible risk of death [11], [15]. This choice not just affects analysis testing and medicine preferences, it can have a psychological impact on patients and their family members. Generally, the estimated expense for inpatient care of patients with CAP is \$7,500. Outpatient care can be priced at as low as \$150 to \$350 [17]. A hospital stay of a patient need to rely on patient age, comorbidities, and the severity of

the presenting illness [11]. Physicians tend to overestimate a patient's risk of death [14]; as a result, several low-risk patients who could be correctly healed as out-patients are confessed for costlier inpatient care. The Pneumonia Severity Index (Table 3) was developed to assist doctors in identifying patients at a greater threat of difficulties and that are more likely to gain from a hospital stay [15]. Researchers established a risk model based on a potential cohort research study of 2,287 patients with CAP in Pittsburgh, Boston, and Halifax, Nova Scotia [16]. By using the design, the authors discovered that 26 to 31 percent of the hospitalized patients were great outpatient candidates, and an extra 13 to 19 percent only needed short hospital monitoring. They validated this model using information from more than 50,000 patients with CAP in 275 U.S. and Canadian medical facilities [17].

Table 3. Pneumonia Severity Index ^[15].

PATIENT CHARACTERISTICS		POINTS		
Demographics				
Male	Age (years)			
Female	Age (years) – 10			
Nursing home resident	+ 10			
Comorbid illness				
Neoplastic disease	+ 30			
Liver disease	+ 20			
Congestive heart failure	+ 10			
Cerebrovascular disease	+ 10			
Renal disease	+ 10			
Physical examination findings				
Altered mental status	+ 20			
Respiratory rate >30 breaths per minute	+ 20			
Systolic blood pressure < 90 mm Hg	+ 20			
Temperature < 35°C (95°F) or >40°C (104°F)	+ 15			
Pulse rate >125 beats per minute	+ 10			
Laboratory and radiographic findings				
Arterial pH < 7.35	+ 30			
Blood urea nitrogen >64 mg per dL (22.85 mmol per L)	+ 20			
Sodium < 130 mEq per L (130 mmol per L)	+ 20			
Glucose >250 mg per dL (13.87 mmol per L)	+ 10			
Hematocrit < 30 percent	+ 10			
Partial pressure of arterial oxygen < 60 mm Hg or oxygen percent saturation < 90 percent	+ 10			
Pleural effusion	+ 10			
<i>Total points:</i>				
POINT TOTAL	RISK	RISK CLASS	MORTALITY % (NO. OF PATIENTS)	RECOMMENDED SITE OF CARE
No predictors	Low	I	0.1 (3,034)	Outpatient
≤ 70	Low	II	0.6 (5,778)	Outpatient
71 to 90	Low	III	2.8 (6,790)	Inpatient (briefly)
91 to 130	Moderate	IV	8.2 (13,104)	Inpatient
>130	High	V	29.2 (9,333)	Inpatient

Antibiotic Treatment

Because the exact causative microorganism is not determined in many patients with CAP, treatment is typically empiric. One of the major variations between U.S. and European standards for therapy of CAP is that all patients in the United States receive treatment for *S. pneumoniae* and irregular microorganisms since CAP is more frequently triggered by these pathogens in North America [18]. Macrolides (e.g., azithromycin [Zithromax], clarithromycin [Biaxin]) can be used for outpatients without any cardiopulmonary disease or current antibiotic usage.

Drug-resistant *S. pneumoniae* is a worry in patients with comorbid health problem or current antibiotic therapy (within previous three months) and need to be treated with an oral beta-lactam antibiotic (e.g., high-dose amoxicillin, amoxicillin/clavulanate [Augmentin], cefpodoxime) combined with a

macrolide. A breathing fluoroquinolone is another option. If a patient has used an antibiotic in the previous three months, a medicine from a various course should be suggested to decrease the threat of pneumococcal resistance. For hospitalized patients not admitted to the ICU, an intravenous respiratory system fluoroquinolone alone or an intravenous beta-lactam antibiotic integrated with a macrolide or doxycycline should be given. A study showed doxycycline to be similar to levofloxacin (Levaquin) in efficiency, span of hospital keep, and failure rate for empiric therapy of CAP; doxycycline is likewise a less costly alternative for hospitalized patients that are not confessed to the ICU [19]. However, the sample dimension in the research was tiny and IDSA/ATS standards recommend doxycycline just for outpatients [12]. All patients with CAP that are admitted to the ICU needs to be treated with double therapy, which is

connected with reduced mortality from bacteremic pneumococcal pneumonia and develops survival in patients with CAP and shock [20]. Some patients with severe CAP, particularly after an episode of influenza or viral disease, that are admitted to the ICU requirement added protection for *S. aureus*, consisting of MRSA. MRSA-associated CAP is identified by a serious, bilateral, necrotizing pneumonia caused by Pantone-Valentine leukocidin and other contaminants.

Duration of treatment for patients with CAP has traditionally been 10 to 14 days, but extra current confirmation recommends a shorter program of as much as seven days is just as reliable [21]. Hospitalized patients may be switched over from intravenous to oral antibiotic therapy after they have medical improvement and have the ability to endure oral medications. An early change from intravenous to oral antibiotics after three days in patients with extreme CAP has actually been shown to be efficient and might lower duration of hospital stay [22]. A program of oral azithromycin after completing intravenous azithromycin and ceftriaxone (Rocephin) is effective and well-tolerated [23].

✚ Conclusion:

CAP is a significant cause of infectious illness mortality, with an increasing prevalence with age. With an aging population, CAP will undoubtedly remain a worldwide problem. Although *Streptococcus pneumoniae* is still the most commonly isolated infection in CAP, the relative incidence of other pathogens has increased. Comorbidities and other risk factors should trigger medical suspicion. Advances in immunization, such as the introduction of PCV and subsequent herd resistance, as well as the potential use of PCV in adults, should help minimize the amount of sickness caused by *S. pneumoniae*. Most CAP patients complain of coughing, dyspnea, pleuritic discomfort, fever or chills, and malaise. Danger and intensity of CAP, consisting of infection with less common microorganisms, boost with older age, cardiopulmonary disease, poor standard useful standing, low socioeconomic status, and recent weight reduction or underweight condition. Lung imaging with chest radiography has actually been the requirement method of identifying pneumonia. Patients who are not admitted to the ICU should be given a respiratory fluoroquinolone or a beta-lactam antibiotic, as well as a macrolide. Physicians must note that one in every four cases of CAP has a viral etiology, which may include a poor response to anti-biotics or abnormal functioning. Motivating recognition and antiviral

treatment, particularly during influenza season, improves outcomes and reduces mortality.

✚ Reference:

1. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax* 2009; 64: iii1–iii55.
2. Froes F, Diniz A, Mesquita M, et al. Hospital admissions of adults with community-acquired pneumonia in Portugal between 2000 and 2009. *Eur Respir J* 2013; 41:1141–1146.
3. Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect Dis* 2013; 13:752–761.
4. Gao H-N, Lu H-Z, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. *N Engl J Med* 2013; 368:2277–2285.
5. Yi L, Guan D, Kang M, et al. Family clusters of avian influenza A H7N9 infection in Guangdong province, China. *J Clin Microbiol* 2015; 53:22–28.
6. Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. *N Engl J Med* 2013; 369:155–163.
7. Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal noninvasive community-acquired pneumonia. *Thorax* 2012; 67:540–545.
8. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44(suppl 2):S27–S72.
9. Beovic B, Bonac B, Kese D, Avsic-Zupanc T, Kreft S, Lesnicar G, et al. Aetiology and clinical presentation of mild community-acquired bacterial pneumonia. *Eur J Clin Microbiol Infect Dis*. 2003;22:584–91.
10. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. *Am J Respir Crit Care Med*. 2001;163:1730–54.
11. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Infectious Diseases

- Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. *Clin Infect Dis*. 2003;37:1405–33.
12. Feagan BG. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. *Pharmacotherapy*. 2001;21(pt 2):S89–94.
 13. Priebe DL, Chambliss ML. Blood cultures not helpful for community-acquired pneumonia. *J Fam Pract*. 2003;52:599–600.
 14. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. *Chest*. 2003;123:1142–50.
 15. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med*. 1997;336:243–50.
 16. Fine MJ, Hough LJ, Medsger AR, Li YH, Ricci EM, Singer DE, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study. *Arch Intern Med*. 1997;157:36–44.
 17. Fine MJ, Pratt HM, Obrosky DS, Lave JR, McIntosh LJ, Singer DE, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. *Am J Med*. 2000;109:378–85.
 18. Mundy LM, Oldach D, Auwaerter PG, Gaydos CA, Moore RD, Bartlett JG, et al. for the Hopkins CAP team. Implications for macrolide treatment in community-acquired pneumonia. *Chest*. 1998;113:1201–6.
 19. Mandell LA. Antibiotics for pneumonia therapy. *Med Clin North Am*. 1994;78:997–1014.
 20. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. for the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. *Clin Infect Dis*. 2000;31:383–421.
 21. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant *Streptococcus pneumoniae* Working Group. *Arch Intern Med*. 2000;160:1399–408.
 22. Mandell LA, Bergeron MC, Gribble MJ, et al. Sequential antibiotic therapy: effective cost management and patient care. *Can J Infect Dis*. 1995;6:306
 23. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. *Pharmacoeconomics*. 2002;20:513–28.